Researchers from the Dana-Farber Cancer Institute and the Tisch Cancer Institute at Mount Sinai Medical School showed that the COVID-19 pandemic caused substantial disruption to clinical trials for cancer treatment and care in 2021, although patient recruitment increased in 2021.
Sarah Bigelow was named executive director of the Clinical Trials Office at the Tulane Cancer Center.
